Acorda's Ampyra is Seen as a Welcomed Addition to Existing Disease-Modifying Agents for the Improvement of Walking Speed in Multiple Sclerosis Patients, According to U.S. Neurologists, Even as Product Access Proves Frustrating

Wednesday, June 2, 2010 General News
Email Print This Page Comment
Font : A-A+

BioTrends Research Group, Inc.

Decision Resources, Inc.

Sharon Funk

Christopher Comfort

404-223-2963

781-296-2597

sfunk@bio-trends.com  

ccomfort@dresources.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook